Comparing the efficacy of generic Imatinib formulations with the original Imatinib as the frontline tyrosine kinase inhibitor in chronic phase chronic myeloid leukemia.

e18024 Background: Tyrosine kinase inhibitors are the mainstay of treatment of chronic myeloid leukemia (CML). Recently, four different generic Imatinib formulations were approved for the frontline treatment of CML in Turkey. All of these commercially available generic Imatinibs are cheaper than the original one. The avarage cost benefit is 130 dollars per box. Our aim was to investigate and compare the efficacy of commercially available generic...